Recommendations of Multiple Sclerosis and Neuroimmunology Section of Polish Neurological Society and Immuno-oncology Section of Polish Society of Oncology on oncological risk in patients with multiple sclerosis undergoing immunomodulatory therapy

被引：0

作者：

Rosciszewska-Zukowska, Iwona ^{[1
]}

Kulakowska, Alina ^{[2
]}

Kalinowska, Alicja ^{[3
]}

Bartosik-Psujek, Halina ^{[1
]}

Mirowska-Guzel, Dagmara ^{[4
]}

Stasiolek, Mariusz ^{[5
]}

Zakrzewska-Pniewska, Beata ^{[6
]}

Brola, Waldemar ^{[7
]}

Wawrzyniak, Slawomir ^{[8
]}

Golebiowski, Marek ^{[9
]}

Mackiewicz, Jacek ^{[10
,11
]}

Kaminska-Winciorek, Grazyna ^{[13
]}

Czarnecka, Anna M. ^{[13
,14
]}

Maciejczyk, Adam ^{[15
,16
]}

Giebel, Sebastian ^{[12
]}

Rutkowski, Piotr ^{[13
]}

Cybulska-Stopa, Bozena ^{[15
,17
]}

Adamczyk-Sowa, Monika ^{[18
]}

机构：

[1] Rzeszow Univ, Inst Med Sci, Dept Pathophysiol, Med Coll, Warzywna 1a St, PL-35310 Rzeszow, Poland

[2] Med Univ Bialystok, Dept Neurol, Bialystok, Poland

[3] Poznan Univ Med Sci, Dept Neurol, Div Neurochem & Neuropathol, Poznan, Poland

[4] Med Univ Warsaw, Dept Expt & Clin Pharmacol, Warsaw, Poland

[5] Med Univ Lodz, Dept Neurol, Lodz, Poland

[6] Med Univ Warsaw, Dept Neurol, Warsaw, Poland

[7] Jan Kochanowski Univ, Dept Gynaecol & Obstet, Coll Med, Kielce, Poland

[8] 10th Mil Res Hosp & Polyclin, Dept Neurol, Bydgoszcz, Poland

[9] Med Univ Warsaw, Dept Clin Radiol 1, Warsaw, Poland

[10] Univ Med Sci, Dept Med & Expt Oncol, Poznan, Poland

[11] Greater Poland Canc Ctr, Dept Diagnost & Canc Immunol, Poznan, Poland

[12] Maria Sklodowska Curie Natl Res Inst Oncol, Dept Bone Marrow Transplantat & Haematol Oncol, Gliwice Branch, Gliwice, Poland

[13] Maria Sklodowska Curie Natl Res Inst Oncol, Dept Soft Tissue Bone Sarcoma & Melanoma, Warsaw, Poland

[14] Polish Acad Sci, Mossakowski Med Res Ctr, Dept Expt Pharmacol, Warsaw, Poland

[15] Lower Silesian Oncol Pulmonol & Haematol Ctr, Dept Clin Oncol, Wroclaw, Poland

[16] Wroclaw Med Univ, Dept Oncol, Wroclaw, Poland

[17] Wroclaw Univ Sci & Technol, Fac Med, Wroclaw, Poland

[18] Med Univ Silesia, Fac Med Sci Zabrze, Dept Physiol Zabrze, PL-40055 Katowice, Poland

来源：

NEUROLOGIA I NEUROCHIRURGIA POLSKA | 2025年 / 59卷 / 01期

关键词：

multiple sclerosis; oncological risk; cancer; immunomodulatory therapy; PLACEBO-CONTROLLED TRIAL; CONTROLLED PHASE-3; CANCER-RISK; INTERFERON BETA-1A; ORAL TERIFLUNOMIDE; FOLLOW-UP; NATALIZUMAB; ALEMTUZUMAB; OCRELIZUMAB; MELANOMA;

D O I：

10.5603/pjnns.101995

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

Multiple sclerosis (MS) is an autoimmune demyelinating disease of the central nervous system (CNS) that is usually diagnosed between the ages of 20 and 40. Changes in the immune system also observed in cancer may suggest a higher prevalence of cancer in the MS patient population. In recent years, many highly effective immunosuppressive drugs have been introduced into disease-modifying therapy (DMT) which may be associated with a higher risk of cancer development in patients with MS. This paper presents current data on the oncological risk of individual drugs. In addition, it provides recommendations on the management for qualifying for DMT and monitoring the safety of the therapy from anoncological perspective.

引用

页码：20 / 32

页数：13

共 98 条

[1] Cancer incidence in multiple sclerosis and effects of immunomodulatory treatments
Achiron, A
Barak, Y
Gail, M
Mandel, M
Pee, D
Ayyagari, R
Rotstein, Z
[J]. BREAST CANCER RESEARCH AND TREATMENT, 2005, 89 (03) : 265 - 270
[2] Cancer Risk for Fingolimod, Natalizumab, and Rituximab in Multiple Sclerosis Patients
Alping, Peter
Askling, Johan
Burman, Joachim
Fink, Katharina
Fogdell-Hahn, Anna
Gunnarsson, Martin
Hillert, Jan
Langer-Gould, Annette
Lycke, Jan
Nilsson, Petra
Salzer, Jonatan
Svenningsson, Anders
Vrethem, Magnus
Olsson, Tomas
Piehl, Fredrik
Frisell, Thomas
[J]. ANNALS OF NEUROLOGY, 2020, 87 (05) : 688 - 699
[3] [Anonymous], 2024, Lemtrada. Summary of product characteristic
[4] [Anonymous], 2024, Aubagio. Summary of product characteristic
[5] [Anonymous], 2024, Ponvory. Summary of product characteristic
[6] [Anonymous], * https://www.ema.europa.eu/en/documents/product-information/orencia-epar-productinformation_pt.pdf
[7] [Anonymous], 2024, Rebif. Summary of product characteristic
[8] [Anonymous], 2024, Myzent. Summary of product characteristic
[9] [Anonymous], 2024, Zeposia. Summary of product characteristic
[10] [Anonymous], 2024, Mavenclad. Summary of product characteristic

← 1 2 3 4 5 6 7 8 9 10 →